Xencor Inc (FRA:XE9)
€ 23.4 0.4 (1.74%) Market Cap: 1.63 Bil Enterprise Value: 1.19 Bil PE Ratio: 0 PB Ratio: 2.35 GF Score: 59/100

Xencor Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2021 / 07:40PM GMT
Release Date Price: €34.52 (-2.13%)
Andrew E. Singer
Credit Suisse Group AG - MD of Healthcare Investment Banking Division

Hi, everyone. It's Andy Singer. Welcome to day 2 of the Credit Suisse Annual Healthcare Conference, virtual, of course, this year. Delighted to be joined by Bassil Dahiyat who is the, as you know, Founder and Chief Executive of Xencor. It's a company that I've known for a long, long time. They've had tremendous success in getting products to patients, pushing the science and really building out the platform into a lot of new and exciting areas beyond the early days in Fc engineering and to bispecifics, engineered cytokines and a lot of other really exciting areas.

So Bassil will take you through the presentation for about 20, 25 minutes, and then we'll have some Q&A. So Bassil, over to you.

Bassil I. Dahiyat
Xencor, Inc. - Co-Founder, CEO, President & Director

Thanks very much, Andy. It's great to be here at CS and to see you virtually today. I'm going to share my screen now. Hopefully, that works. You're seeing slides. Is that correct?

Great. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot